Biological products are complex molecules derived from genetically modified proteins and human genes. These products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies. Biological products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies. Monoclonal Antibodies are a class of antibodies that are derived from a single ancestral cell. These antibodies have a tendency to grow indefinitely and are very particular for a location in the body derived from a single clone. Further, biological drugs have aided in the treatment of many serious and chronic illnesses to a great extent. These are one of the most available advanced therapies and are able to treat cancer, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases.
Biological Market is estimated to reach $XXX billion by 2026; growing at a CAGR of XX% from 2018 to 2026. In 2017, 12 biologics were found to be approved in the USA, 10 in European Union and 7 in Japan. There found over 1000 biologics under development, which will drive the biologics market in the future. Cancer is the therapeutic area with a maximum number of biologics under development and Alzheimer's has found the least number. Of the total biologics market across the globe, Monoclonal antibodies (mAbs) accounted for a share of xx% in 2018 and were worth $xx billion. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period.
The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. With the launch of the first therapeutic monoclonal antibody in 1986, the class of monoclonal antibodies has expanded substantially so that, today over 74 monoclonal antibodies based therapeutics have been approved for commercial use across the globe.
An increasing prevalence of lifestyle and chronic diseases, growing elderly population, loss of patent exclusivity of the leading biologic drugs, growing demand and higher acceptability for innovative therapies, and rising capital investments in various R&D programs are going to boost the growth of the global biological market. Further, government initiatives supporting the usage of biological drugs also drive the growth of the market. Moreover, the high costs of these drugs and the possibility of adverse effects may hinder the growth of the market. Furthermore, technological advancements and cost reduction might provide significant scope for the market in future years.
The global biological market is categorized into product type and geography.
By product type: Therapeutic protein (Enbrel, Neulasta, Avones, Lantus, Rebif, Humalog, Epogen, Levemir, Victoza, Aranesp, Betaseron, Neupogen, Eylea and Others), monoclonal antibody (Humira, Remicade, Rituxan, Avastin, Herceptin, Lucentis, and Others) and vaccine (Prevnar 13, Gardasil, Fluzone, Varivax, Cervarix, and Others).
The monoclonal antibodies segment accounted for the maximum share in 2018 because of higher usage of this category of drugs in different therapeutic areas of treatment. Vaccines are anticipated to show significant growth during the forecast period due to the growing adoption of vaccines in the treatment of infectious diseases in the near future.
By geography: North America, Europe, Asia-Pacific, and Rest of the World (RoW). The North American healthcare biologics market dominated the global market and is estimated to show a similar trend during the forecast period. Furthermore, the presence of well-established companies, like Johnson & Johnson, Bristol-Myers Squibb, AbbVie Inc., and other key players, is making biologics more accessible in the United States.
They key companies involved in this market include Baxter International Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., Biogen Inc., GlaxoSmithKline Plc, Novartis AG, Eli Lilly and Co., Pfizer Inc., and Abbott Laboratories, among others.
Report Description: The report covers in-depth analysis on Biological/Monoclonal Antibodies Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Cancer, ulcerative colitis, rheumatoid arthritis, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Biological/Monoclonal Antibodies Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.